FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308591063> ?p ?o ?g. }

• W4308591063 endingPage "1227" @default.
• W4308591063 startingPage "1217" @default.
• W4308591063 abstract "Levodopa remains the gold standard for the treatment of Parkinson's disease, but its long-term use is associated with motor complications whose management is still a significant challenge. Safinamide is a multimodal drug with proven efficacy as an adjunct to levodopa.The objective of this study was to investigate the efficacy and safety of safinamide as an add-on to levodopa in Chinese patients with Parkinson's disease with motor fluctuations.The XINDI study was a phase III, randomized, double-blind, placebo-controlled, multicenter study, with a 2-week screening period and a 16-week treatment period. The starting dose of safinamide (or placebo) was 50 mg once daily, increased to 100 mg once daily at day 15. Patients aged ≥ 18 years, with idiopathic Parkinson's disease of >3 years duration, Hoehn and Yahr stage 1-4, and daily OFF time ≥ 1.5 h, were eligible. Patients should follow a stable oral levodopa regimen and may receive concomitant treatment with stable doses of other anti-Parkinson drugs, except monoamine oxidase-B inhibitors. Patients with severe disabling peak-dose or biphasic dyskinesia, unpredictable or widely swinging fluctuations, other forms of parkinsonism, a history of dementia or severe cognitive dysfunction, major psychiatric illnesses, and/or clinically significant medical illnesses were excluded. The primary efficacy endpoint was the change from baseline to week 16 in the mean daily OFF time. Secondary efficacy endpoints included the Unified Parkinson's Disease Rating Scale, the Numerical Rating Scale, the Clinical Global Impression scale, and the 39-Item Parkinson's Disease Questionnaire scale. The statistical analysis of the efficacy parameters was conducted using an analysis of co-variance, except for the Clinical Global Impression scale scores that were assessed using the Wilcoxon-Mann-Whitney test. Safety was evaluated through the frequency of adverse events and serious adverse events, physical examination, vital signs, 12-lead electrocardiograms, and laboratory exams. All safety endpoints were summarized using descriptive statistics.The trial enrolled 307 patients. At week 16, the difference in the change of the mean total daily OFF time between safinamide and placebo groups was 1.10 h (p < 0.0001). This change was significantly greater in the safinamide group starting from week 2, suggesting a rapid onset of drug efficacy. ON time, Unified Parkinson's Disease Rating Scale, Clinical Global Impression scale, and the 39-Item Parkinson's Disease Questionnaire showed statistically significant improvements. There were no significant between-group differences for adverse events or serious adverse events.Safinamide, as add-on therapy to levodopa, significantly reduced motor fluctuations and improved motor symptoms and quality of life of Chinese patients with idiopathic Parkinson's disease. The improvements observed in the Unified Parkinson's Disease Rating Scale total and motor scores were also clinically significant. No safety concerns were identified, confirming the good tolerability profile of the drug.NCT03881371, registered on 19 March, 2019, https://clinicaltrials.gov/NCT03881371 ." @default.
• W4308591063 created "2022-11-12" @default.
• W4308591063 creator A5001996060 @default.
• W4308591063 creator A5005215105 @default.
• W4308591063 creator A5006012404 @default.
• W4308591063 creator A5011891513 @default.
• W4308591063 creator A5015760127 @default.
• W4308591063 creator A5015900881 @default.
• W4308591063 creator A5019633275 @default.
• W4308591063 creator A5021488560 @default.
• W4308591063 creator A5024333035 @default.
• W4308591063 creator A5025014317 @default.
• W4308591063 creator A5026662451 @default.
• W4308591063 creator A5027255941 @default.
• W4308591063 creator A5029257310 @default.
• W4308591063 creator A5031602481 @default.
• W4308591063 creator A5034790256 @default.
• W4308591063 creator A5041069392 @default.
• W4308591063 creator A5041794855 @default.
• W4308591063 creator A5046881768 @default.
• W4308591063 creator A5048425923 @default.
• W4308591063 creator A5049845572 @default.
• W4308591063 creator A5051310867 @default.
• W4308591063 creator A5051411025 @default.
• W4308591063 creator A5057247700 @default.
• W4308591063 creator A5057491110 @default.
• W4308591063 creator A5062755510 @default.
• W4308591063 creator A5072714534 @default.
• W4308591063 creator A5075583982 @default.
• W4308591063 creator A5076153014 @default.
• W4308591063 creator A5079953530 @default.
• W4308591063 creator A5082383658 @default.
• W4308591063 creator A5082580072 @default.
• W4308591063 creator A5085136795 @default.
• W4308591063 creator A5086704861 @default.
• W4308591063 creator A5089000611 @default.
• W4308591063 creator A5089070056 @default.
• W4308591063 date "2022-11-01" @default.
• W4308591063 modified "2023-10-18" @default.
• W4308591063 title "The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson’s Disease with Motor Fluctuations" @default.
• W4308591063 cites W1547633323 @default.
• W4308591063 cites W1631523450 @default.
• W4308591063 cites W1983670218 @default.
• W4308591063 cites W2019345577 @default.
• W4308591063 cites W2022826257 @default.
• W4308591063 cites W2030672557 @default.
• W4308591063 cites W2035942308 @default.
• W4308591063 cites W2045123689 @default.
• W4308591063 cites W2051086599 @default.
• W4308591063 cites W2056798863 @default.
• W4308591063 cites W2064963539 @default.
• W4308591063 cites W2064996887 @default.
• W4308591063 cites W2066221781 @default.
• W4308591063 cites W2078208735 @default.
• W4308591063 cites W2085752173 @default.
• W4308591063 cites W2089574993 @default.
• W4308591063 cites W2115222037 @default.
• W4308591063 cites W2122085123 @default.
• W4308591063 cites W2145954079 @default.
• W4308591063 cites W2171241738 @default.
• W4308591063 cites W2214196459 @default.
• W4308591063 cites W2431340556 @default.
• W4308591063 cites W2461435105 @default.
• W4308591063 cites W2504570392 @default.
• W4308591063 cites W2522915615 @default.
• W4308591063 cites W2563082987 @default.
• W4308591063 cites W258430117 @default.
• W4308591063 cites W2743373424 @default.
• W4308591063 cites W2811061566 @default.
• W4308591063 cites W2976680412 @default.
• W4308591063 cites W3023737799 @default.
• W4308591063 cites W3094227256 @default.
• W4308591063 cites W3132695853 @default.
• W4308591063 cites W3168562437 @default.
• W4308591063 cites W4232719749 @default.
• W4308591063 doi "https://doi.org/10.1007/s40263-022-00958-6" @default.
• W4308591063 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36346534" @default.
• W4308591063 hasPublicationYear "2022" @default.
• W4308591063 type Work @default.
• W4308591063 citedByCount "6" @default.
• W4308591063 countsByYear W43085910632023 @default.
• W4308591063 crossrefType "journal-article" @default.
• W4308591063 hasAuthorship W4308591063A5001996060 @default.
• W4308591063 hasAuthorship W4308591063A5005215105 @default.
• W4308591063 hasAuthorship W4308591063A5006012404 @default.
• W4308591063 hasAuthorship W4308591063A5011891513 @default.
• W4308591063 hasAuthorship W4308591063A5015760127 @default.
• W4308591063 hasAuthorship W4308591063A5015900881 @default.
• W4308591063 hasAuthorship W4308591063A5019633275 @default.
• W4308591063 hasAuthorship W4308591063A5021488560 @default.
• W4308591063 hasAuthorship W4308591063A5024333035 @default.
• W4308591063 hasAuthorship W4308591063A5025014317 @default.
• W4308591063 hasAuthorship W4308591063A5026662451 @default.
• W4308591063 hasAuthorship W4308591063A5027255941 @default.
• W4308591063 hasAuthorship W4308591063A5029257310 @default.
• W4308591063 hasAuthorship W4308591063A5031602481 @default.
• W4308591063 hasAuthorship W4308591063A5034790256 @default.
• W4308591063 hasAuthorship W4308591063A5041069392 @default.

• next